ORCHPHARMA.NSORCHPHARMA.NSNSE
Loading
EBITDA Over TimeContracting
Percentile Rank33
3Y CAGR-22.4%
5Y CAGR+0.6%
Studio
Year-over-Year Change

Earnings before interest, taxes, depreciation, and amortization

3Y CAGR
-22.4%/yr
vs -8.0%/yr prior
5Y CAGR
+0.6%/yr
Recent deceleration
Acceleration
-14.4pp
Decelerating
Percentile
P33
Within normal range
vs 5Y Ago
1x
Modest growth
Streak
1 yr
Consecutive declineContracting
PeriodValueYoY Change
TTM$668.63M-53.8%
2025$1.45B+1.9%
2024$1.42B-0.7%
2023$1.43B+130.0%
2022$621.38M-4.4%
2021$650.03M+24.1%
2020$523.95M-73.8%
2019$2.00B+454.6%
2018$359.98M+164.3%
2017$-559.56M-